Fractyl Health, Inc. (GUTS)
NASDAQ: GUTS · IEX Real-Time Price · USD
6.22
+0.16 (2.64%)
At close: May 9, 2024, 4:00 PM
6.17
-0.05 (-0.80%)
After-hours: May 9, 2024, 7:58 PM EDT
Fractyl Health Revenue
In the year 2023, Fractyl Health had annual revenue of $120.00K. Revenue in the quarter ending December 31, 2023 was $7.00K.
Revenue (ttm)
$120.00K
Revenue Growth
n/a
P/S Ratio
2,481.69
Revenue / Employee
$1,277
Employees
94
Market Cap
297.80M USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 120.00K | - | - |
Dec 31, 2022 | 0 | - | - |
Dec 31, 2021 | 0 | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionGUTS News
- 1 day ago - Fractyl Health to Present at BofA Securities 2024 Health Care Conference - GlobeNewsWire
- 2 days ago - Fractyl Health to Report First Quarter 2024 Financial Results and Provide Business Updates on May 13, 2024 - GlobeNewsWire
- 9 days ago - Fractyl Health Announces Multiple Presentations at the Upcoming Digestive Disease Week (DDW) 2024 Conference and the German Diabetes Association (DDG) Annual Meeting - GlobeNewsWire
- 5 weeks ago - Fractyl Health Expands Leadership with Appointment of Adrian Kimber as Chief Commercial Officer to Spearhead Anticipated Launch Preparation as the Company Conducts Two Pivotal Studies for Revita in Obesity and Type 2 Diabetes - GlobeNewsWire
- 5 weeks ago - Fractyl Health Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update - GlobeNewsWire
- 5 weeks ago - Fractyl Health Receives FDA IDE Approval for the Revita® Remain-1 Pivotal Study of Weight Maintenance in Obesity after Discontinuation of GLP-1 Based Drugs - GlobeNewsWire
- 7 weeks ago - Top 5 Health Care Stocks Which Could Rescue Your Portfolio In March - Inspire Veterinary (NASDAQ:IVP), Fractyl Health (NASDAQ:GUTS) - Benzinga
- 2 months ago - UPDATE -- Fractyl Health Announces New Results From Its Rejuva® Platform Demonstrating Potent and Durable Effects of a Single Dose of a Human GLP-1 Pancreatic Gene Therapy Transgene Compared to Semaglutide in the db/db Mouse Model of Diabetes and Obesity - GlobeNewsWire